Balancing HIV testing efficiency with HIV case-identification among children and adolescents (2-19 years) using an HIV risk screening approach in Tanzania.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 23 07 2020
accepted: 22 04 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 21 10 2021
Statut: epublish

Résumé

To optimize HIV testing resources, programs are moving away from universal testing strategies toward a risk-based screening approach to testing children/adolescents, but there is little consensus around what defines an optimal risk screening tool. This study aimed to validate a 12-item risk screening tool among children and adolescents and provide suggested fewer-item tool options for screening both facility out-patient and community populations by age strata (<10 and ≥10 years). Children/adolescents (2-19 years) with unknown HIV status were recruited from a community-based vulnerable children program and health facilities in 5 regions of Tanzania in 2019. Lay workers administered the screening questions to caregivers/adolescents; nurses enrolled those eligible for the study and tested all participants for HIV. For each screening item, we estimated sensitivity, specificity, positive predictive value and negative predictive value and associated 95% confidence intervals (CI). We generated a score based on the count of items with a positive risk response and fit a receiver operating characteristic curve to determine a cut-off score. Sensitivity, specificity, positive predictive value (PPV; yield) and number needed to test to detect an HIV-positive child (NNT) were estimated for various tool options by age group. We enrolled 21,008 children and adolescents. The proportion of undiagnosed HIV-positive children was low (n = 76; 0.36%; CI:0.29,0.45%). A screening algorithm based on reporting at least one or more items on the 10 to 12-item tool had sensitivity 89.2% (CI:79.1,95.6), specificity 37.5% (CI:36.8,38.2), positive predictive value 0.5% (CI:0.4,0.6) and NNT = 211. An algorithm based on at least two or more items resulted in lower sensitivity (64.6%), improved specificity (69.1%), PPV (0.7%) and NNT = 145. A shorter tool derived from the 10 to 12-item screening tool with a score of "1" or more on the following items: relative died, ever hospitalized, cough, family member with HIV, and sexually active if 10-19 years performed optimally with 85.3% (CI:74.6,92.7) sensitivity, 44.2% (CI:43.5,44.9) specificity, 0.5% (CI:0.4,0.7) PPV and NNT = 193. We propose that different short-tool options (3-5 items) can achieve an optimal balance between reduced HIV testing costs (lower NNT) with acceptable sensitivity. In low prevalence settings, changes in yield may be negligible and NNT may remain high even for an effective tool.

Identifiants

pubmed: 33956881
doi: 10.1371/journal.pone.0251247
pii: PONE-D-20-22942
pmc: PMC8101905
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0251247

Subventions

Organisme : PEPFAR
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS Med. 2017 Jul 25;14(7):e1002360
pubmed: 28742829
AIDS. 2013 Nov;27 Suppl 2:S235-45
pubmed: 24361633
AIDS. 2016 Mar 13;30(5):779-85
pubmed: 26588175
Trop Med Int Health. 2011 Mar;16(3):349-55
pubmed: 21176006
Bull World Health Organ. 2003;81(12):858-66
pubmed: 14997238
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S16-S21
pubmed: 29994915
Lancet HIV. 2016 Oct;3(10):e473-81
pubmed: 27658876
Implement Sci. 2013 Aug 26;8:97
pubmed: 23972055
Bull World Health Organ. 2012 Sep 1;90(9):652-658B
pubmed: 22984309
Arch Dis Child. 2011 Jan;96(1):67-72
pubmed: 21047830
PLoS Med. 2014 May 27;11(5):e1001649
pubmed: 24866209
J Int AIDS Soc. 2015 Oct 14;18:20182
pubmed: 26471265
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):e83-e89
pubmed: 27846074
AIDS. 2019 Feb 1;33(2):349-352
pubmed: 30557162
AIDS. 2013 Feb 20;27(4):617-26
pubmed: 23364442
PLoS One. 2019 May 6;14(5):e0214251
pubmed: 31059507
PLoS One. 2020 Jun 2;15(6):e0233590
pubmed: 32484815
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):352-357
pubmed: 29995704
Trop Med Int Health. 2015 Aug;20(8):1015-32
pubmed: 25877007
Trop Med Int Health. 2017 Aug;22(8):1021-1029
pubmed: 28544728
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S98-S106
pubmed: 29994831
Trop Doct. 2007 Jan;37(1):45-7
pubmed: 17326892
BMC Pediatr. 2018 Sep 25;18(1):309
pubmed: 30253758

Auteurs

Gretchen Antelman (G)

Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania.

Michelle M Gill (MM)

Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States of America.

Ola Jahanpour (O)

Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania.
Department of Epidemiology and Biostatistics, The Institute of Public Health, Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Roland van de Ven (R)

Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania.

Catherine Kahabuka (C)

CSK Research Solutions, Dar es Salaam, Tanzania.

Asheri Barankana (A)

Pact, Dar es Salaam, Tanzania.

Sharon Lwezaura (S)

National AIDS Control Program, Ministry of Health, Community Development, Gender, Elderly and Children, Dodoma, Tanzania.

Naftali Ngondi (N)

Department of Social Welfare, Ministry of Health, Community Development, Gender, Elderly and Children, Dodoma, Tanzania.

Alison Koler (A)

Pact, Washington DC, United States of America.

Peris Urasa (P)

National AIDS Control Program, Ministry of Health, Community Development, Gender, Elderly and Children, Dodoma, Tanzania.

Rhoderick Machekano (R)

Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH